(Q44938175)

7 December 2017

title

The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers (English)

1 reference

7 December 2017

1 reference

1 reference

1

1 reference

7 December 2017

Zhang-Jin Zhang

2

1 reference

7 December 2017

Wen-Biao Li

3

1 reference

7 December 2017

Yi-Min Zhai

4

1 reference

7 December 2017

Zhuo-Ji Cai

5

1 reference

7 December 2017

Yong-Zhen Weng

6

1 reference

7 December 2017

Rong-Hua Zhu

7

1 reference

7 December 2017

Jing-Ping Zhao

8

1 reference

7 December 2017

Hong-Hao Zhou

9

1 reference

7 December 2017

publication date

1 July 2004

1 reference

The Journal of Clinical Pharmacology

7 December 2017

published in

1 reference

7 December 2017

volume

44

1 reference

7 December 2017

issue

7

1 reference

7 December 2017

page(s)

785-792

1 reference

Severe depression: is there a best approach?

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Clinical pharmacokinetics of fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Ethnicity and antipsychotic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Influence of fluoxetine on olanzapine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Pharmacokinetics and pharmacodynamics of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266621

21 January 2018

Identifiers

DOI

10.1177/0091270004266621

1 reference

release_qstt3hopmfepdmlotkvqxra35a

7 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qstt3hopmfepdmlotkvqxra35a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference